Immune activation and viraemia: Reciprocal interactions in disease pathogenesis

Journal of HIV Therapy

Volumn 13, Issue 4, 2008, Pages 76-78

  Kelleher, Peter ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; DARUNAVIR; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INDINAVIR; INTEGRASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VIRUS DNA; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL RESISTANCE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG TREATMENT FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IC 50; LYMPHOCYTE PROLIFERATION; MUCOSAL IMMUNITY; NONHUMAN; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE ACTIVATION; VIREMIA; VIRUS IMMUNITY; VIRUS LOAD; VIRUS MUTATION; VIRUS PATHOGENESIS; VIRUS REPLICATION; ANIMAL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; REVIEW; VIROLOGY;

ANIMALS; ANTI-HIV AGENTS; HIV INFECTIONS; HIV-1; HUMANS; VIREMIA;

EID: 65649101904     PISSN: 14620308     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol, 2008, 214, 231-234.
2. Pandrea I, Sodora DL, Silvestri G, Apetrei C. Into the wild: simian immunodeficiency virus (SIV) infection in natural hosts. Trends Immunol, 2008, 29, 419-428.
3. Silvestri G, Sodora DL, Koup RA et al. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity, 2003, 18, 441-452.
4. Klatt NR, Villinger F, Botik P et al. Availability of activated CD4 T cells dictates the levels of viremia in naturally SIV-infected sooty mangabeys. J Clin Invest, 2008, 11, 2039-2049.
5. Giorgi JV, Liu Z, Hultin LE et al. Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. The Los Angeles Center, Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr, 1993, 6, 904-912.
6. Bofill M, Mocroft A, Lipman M et al. Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. AIDS, 1996, 8, 827-834.
7. Liu Z, Cumberland WG, Hultin LE et al. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol, 1997, 16, 83-92.
8. Giorgi JV, Hultin LE, McKeating JA et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis, 1999, 179, 859-870.
9. Hazenberg MD, Otto SA, van Benthem BH et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS, 2003, 17, 1881-1888.
10. Sousa AE, Carneiro J, Meier-Schellersheim M et al. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol, 2002, 169, 3400-3406.
11. Anthony KB, Yoder C, Metcalf JA et al. Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover. J Acquir Immune Defic Syndr, 2003, 33, 125-133.
12. Hunt PW, Martin JN, Sinclair E et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis, 2003, 187, 1534-1543.
13. Benveniste O, Flahault A, Rollot F et al. Mechanisms involved in the low level regeneration of CD4+ cells in HIV-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. J Infect Dis, 2005, 191, 1671-1679.
14. Goicoechea M, Smith DM, Liu L et al. Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers and cellular HIV-1 DNA. J Infect Dis, 2006, 194, 129-137.
15. Sodora DL, Silvestri G. Immune activation and AIDS pathogenesis. AIDS, 2008, 22, 439-446.
16. Brenchley JM, Price DA, Schacker TW et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med, 2006, 12, 1365-1371.
17. Rouse BT, Sarangi PP, Suvas S. Regulatory T cells in viral infections. Immunol Rev, 2006, 212, 272-286.
18. Maldarelli F, Palmer, King MS et al. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PL0S Pathog, 2008, 3, e46.
19. Palmer S, Maldarelli F, Wiegand A et al. Low level viraemia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A, 2008, 105, 3879-3884.
20. Steel A, Cox AE, Shamji MH et al. HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8 T cell activation. Antiviral Ther, 2007, 12, 971-975.
21. Karlsson AC, Younger SR, Martin JN et al. Immunologic and virologic evolution during periods of intermittent and persistent low-level viraemia. AIDS, 2004, 18, 981-989.
22. Shen L, Siliciano RF. Viral reservoirs, residual viremia and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol, 2008, 122, 22-28.
23. Sharkey ME, Teo I, Greenough T et al. Persistence of episomal HIV 1 infection intermediates in patients on highly active anti-retroviral therapy. Nat Med, 2000, 6, 76-81.
24. Sharkey M, Tirques K, Kuritzkes DR, Stevenson M. In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J Virol, 2005, 79, 5203-5210.
25. Butler SL, Johnson EP, Bushman FD. Human immunodeficiency virus cDNA metabolism: notable stability of two-long terminal repeat circles. J Virol, 2002, 76, 3737-3747.
26. Pierson TC, Kieffer TC, Ruff CT et al. Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol, 2002, 76, 4138-4144.
27. Tobins NH, Learn GH, Holte SE et al. evidence that low level viraemia during effective antiretroviral therapy results from two processes: expression of archival virus and replication of virus. J Virol, 2005, 79, 9625-9634.
28. Havlir D, Strian MC, Clerici M et al. Productive infection maintains a dynamic steady state of residual viraemia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years. J Virol, 2003, 77, 11212-11219.
29. Ramratnam B, Ribeiro R, Chung C et al. Intensification of antiretroviral therapy accelerates the decay of HIV-1 latent reservoir and decreases but does not eliminate ongoing virus replication. J Acquir Immune Defic Syndr, 2004, 35, 33-37.
30. Persaud D, Siberry GK, Ahonkhai A et al. Continued production of drug sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J Virol, 2004, 78, 986-1979
31. Kieffer TL, Finucane MM, Nettles RE. Genotypic resistance analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads. J Infect Dis, 2004, 189, 1452-1465.
32. Bailey JR, Sedaghat AR, Kieffer T et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4 T cells. J Virol, 2006, 80, 6441-6457.
33. Zhang L, Ramratnam B, Tenner-Racz K et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med, 1999, 340, 1605-1613.
34. Sedaghat AR, Siliciano JD, Brennan TP et al. Limits on the replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART. PLoS Pathog, 2008, 3, e122.
35. Sedaghat AR, Siliciano RF, Wilke CO. Low level HIV-1 replication and the dynamics of resting CD4 T cell reservoir for HIV-1 in the setting of ART. BMC Infect Dis, 2008, 8, 2 (doi 10.1186/1471-2334/8/2).
36. Shen L, Peterson S, Sedaghat AR et al. Dose response curve sets class specific limits on inhibitory potential of anti-HIV drugs. Nat Med, 2008, 14, 762-766.